LPL and metabolic syndrome: Although some of these studies have focused on genomic regions that are confirmed to harbor dyslipidemia-predisposing loci, such as APOB, CETP, LIPC and LPL[21], [22], [24]–[28], no exhaustive studies testing whether GWAS-discovered loci [10], [29], [30] modify response to treatments have been previously reported.